PL9643 Ophthalmic Solution

DRUG2 trials

Sponsors

ORA, Inc., Palatin Technologies, Inc

Conditions

Dry EyeDry Eye DiseaseDry Eye Syndromes

Phase 2

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

CompletedNCT04268069

ORA, Inc.Dry Eye Disease

Start: 2020-02-14End: 2020-10-05Updated: 2020-11-13

Phase 3

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

CompletedNCT05201170

Palatin Technologies, IncDry Eye, Dry Eye Syndromes

Start: 2021-12-30End: 2023-11-21Updated: 2024-10-17

Related Papers

Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease

Journal of Ocular Pharmacology and Therapeutics2023-09-079 citations